Disease State Platelet Presentation Volume 2 Presented By: Name.

Slides:



Advertisements
Similar presentations
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
Advertisements

Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease Aspirin and clopidogrel: - Reduce the risks of myocardial infarction, ischemic.
ISCHAEMIC HEART DISEASE Acute Coronary Syndromes JD Marx Department of Cardiology University of the Free State.
Access Site Complications Nick Cheshire MD FRCS, Professor of Vascular Surgery Imperial College Healthcare St Mary’s Hospital Campus.
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
Anticoagulation? Antiplatelet? What’s the Score? COPYRIGHT © 2015, ALL RIGHTS RESERVED From the Publishers of.
Leadership. Knowledge. Community. Antiplatelet Therapy for Secondary Prevention Beyond One Year Following ACS or PCI Working Group: Anil Gupta MD, FRCPC,
Call for CASES Leszek D. Stachaczyk, MD Pawel Buszman, MD, FESC, FSCAI American Heart of Poland, Ustroñ, Poland & CCU, Upper-Silesian Center of Cardiology,
Ten Points to Remember from the 2007 STEMI Guideline Update Based on the 2007 Focused Update of the 2004 Guidelines for the Management of Patients With.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.
ACUTE CORONARY SYNDROMES:
Coronary Stenting: Drug-eluting vs Bare-metal Natalie Cleaver, PA-S Lock Haven University PA Program Evidence Based Medicine February 26, 2009.
Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.
Initiating Antiplatelet Therapy in Patients with Atherothrombosis
PRODIGY Objective Study Design Primary Composite Endpoint
PRACTICAL RECOMMENDATIONS ON ANTI- THROMBOTIC TREATMENT IN PATIENTS TREATED WITH DRUG-ELUTING STENTS Giuseppe Biondi-Zoccai Ospedale S. Giovanni Battista.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.
The Black Back Yard of D.E.S [D.ES Pitfalls) Ehud Grenadier M.D H.M.C, Assuta, Rambam Med. Ctrs. Israel The Black Back Yard of D.E.S [D.ES Pitfalls) Ehud.
The Primary and Secondary Prevention of Cardiovascular Disease Per Olav Vandvik, MD, PhD A. Michael Lincoff, MD Joel M. Gore, MD David Gutterman, MD, FCCP.
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with.
수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2014 AHA/ACC Guideline for the Management of Patients.
2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.
The Primary and Secondary Prevention of Cardiovascular Disease
Disclosures Speaker’s bureau: Research support: Consulting: Equity
Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;
Major recommendation for statin therapy for ASCVD prevention
NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.
CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.
DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.
Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype status. Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype.
Catheter-Based Treatment of Coronary Artery Disease
Preventing Thrombotic Complications in ACS: State of the Art
Atrial Fibrillation and PCI
Glenn N. Levine et al. JACC 2016;68:
Glenn N. Levine et al. JACC 2016;68:
Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Antiplatelet Therapy and Secondary Prevention
Robert W. Yeh et al. JACC 2017;70:
Terms of Use. Terms of Use.
Section 5: Intervention and drug therapy
Effective interprofessional communication is vital when planning surgical procedures for medically complicated individuals on anticoagulants. Thromboembolism.
AF and PCI in Practice.
ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Nat. Rev. Cardiol. doi: /nrcardio
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease  Glenn N. Levine, MD, FACC, FAHA,
Peter K. Smith, MD  The Journal of Thoracic and Cardiovascular Surgery 
Peter K. Smith, MD  The Annals of Thoracic Surgery 
NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.
TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES
What oral antiplatelet therapy would you choose?
Khurram Nasir et al. JACC 2015;66:
Roberta Rossini et al. JCIN 2018;11:
ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.
Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.
The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing
Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.
Glenn N. Levine et al. JACC 2011;58:e44-e122
C-3. Clinical trial updates: GP IIb/IIIa inhibitors
Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;
Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

Disease State Platelet Presentation Volume 2 Presented By: Name

An ACS Case Study: Mr. Jacobs

Case Study: Pre-Angiogram Lesion in the mid LADLesion in the mid LAD Proceeded with PCIProceeded with PCI

PCI SuccessfulPCI Successful Post PCI MedsPost PCI Meds ACE inhibitorACE inhibitor Beta-blockerBeta-blocker StatinStatin Dual antiplatelet therapyDual antiplatelet therapy Case Study: Post-Angiogram

Post PCI Arterial Environment Arterial wall damage and plaque disruption Exposure of thrombotic substrates SMC

Stent Thrombosis AdhesionActivationAggregation

Dual Antiplatelet Therapy in the PCI Patient Manages the prothrombotic environment Reduces risk of MI and death Platelet Monolayer

The Progression of Atherosclerotic Disease Continues Plaque formation is likely to continue in this ACS patient

Spontaneous Rupture and Thrombus Formation

Premature Discontinuation of Dual Antiplatelet TherapyAtherothrombosis

Increased risk of MI and death

Minimizing the Risk of Atherothrombotic Events in the ACS patient Percutaneous Coronary InterventionPercutaneous Coronary Intervention Long-term medical managementLong-term medical management Dual antiplatelet therapyDual antiplatelet therapy Lifestyle changesLifestyle changes Smith SC Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). American Heart Association Website. Available at:

Dual Antiplatelet Therapy Continued in this ACS Patient Platelet monolayer is formed and activation is better managed

Managing the Risks: A Summary Long term dual antiplatelet therapy helps prevent atherothrombosis caused by PCI and spontaneous plaque rupture

ACC/AHA/SCAI 2005 Guidelines for PCI Current guidelines recommend dual antiplatelet therapy be given ideally up to 12 months in patients who have undergone PCI and who are not at a high risk of bleeding. Smith SC Jr, Feldman TE, Hirschfeld JW Jr, Jacobs AK, Kern MJ, King SB III, Morrison DA, O’Neill WW, Schaff HV, Whitlow PL, Williams DO. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). American Heart Association Website. Available at: